•
PB
PBM
Psyence Biomedical Ltd. Common Shares
polygon--
Price Chart
Market Cap
4.28M
Volume
2.47M
52W High
$17.37
52W Low
$0.61
Open
$0.76
Prev Close
$4.19
Day Range
0.64 - 0.91
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Latest News
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
GlobeNewswire Inc.•Dec 9
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
GlobeNewswire Inc.•Nov 3
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
Benzinga•Dec 20
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs
Benzinga•Oct 31
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
Benzinga•Sep 19
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Benzinga•Sep 6
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
GlobeNewswire Inc.•Aug 30
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire Inc.•May 17